ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.
ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.
11/18/24, 1:21 PM
Location
menlo parkMoney raised
$15 million
Industry
biotechnology
health care
Investors
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their collaboration with Intellia Therapeutics. The funding will aid in the development of a gene editing therapy intended for lung cells of individuals suffering from cystic fibrosis.
Company Info
Location
1455 adams drive
menlo park, california, united states
Additional Info
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.